Smith & Nephew plc

LSE SN.L

Smith & Nephew plc Dividend Yield on January 14, 2025: 3.14%

Smith & Nephew plc Dividend Yield is 3.14% on January 14, 2025, a 14.55% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.
  • Smith & Nephew plc 52-week high Dividend Yield is 3.85% on December 20, 2024, which is 22.73% above the current Dividend Yield.
  • Smith & Nephew plc 52-week low Dividend Yield is 2.36% on September 10, 2024, which is -24.90% below the current Dividend Yield.
  • Smith & Nephew plc average Dividend Yield for the last 52 weeks is 2.78%.
Key data
Date Dividend Yield Free Cash Flow Yield Earnings Yield Enterprise Value (EV)
Market news
Loading...
LSE: SN.L

Smith & Nephew plc

CEO Dr. Deepak S. Nath Ph.D.
IPO Date July 1, 1988
Location United Kingdom
Headquarters Building 5
Employees 18,000
Sector Health Care
Industries
Description

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Similar companies

WPP.L

WPP plc

USD 8.87

0.75%

REL.L

RELX PLC

USD 45.94

0.03%

SGE.L

The Sage Group plc

USD 15.55

0.17%

SMIN.L

Smiths Group plc

USD 20.97

-0.72%

CPG.L

Compass Group PLC

USD 32.45

-0.58%

StockViz Staff

January 15, 2025

Any question? Send us an email